AHA 2024 - The BRAIN-AF trial examined whether rivaroxaban is superior to placebo in preventing cognitive decline, stroke, or TIA in individuals with AF and a low risk of stroke. Léna Rivard shares the results and future perspectives.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
AHA 2024 - The BRAIN-AF trial examined whether rivaroxaban is superior to placebo in preventing cognitive decline, stroke, or TIA in individuals with AF and a low risk of stroke. Léna Rivard shares the results and future perspectives.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Léna Rivard is an electrophysiologist andcardiology researcher at the Montreal Heart Institute in Montreal, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024
AHA 2024 - The BRAIN-AF trial examined whether rivaroxaban is superior to placebo in preventing cognitive decline, stroke, or TIA in individuals with AF and a low risk of stroke. Léna Rivard shares the results and future perspectives.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Léna Rivard is an electrophysiologist andcardiology researcher at the Montreal Heart Institute in Montreal, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024
Stay current with the best on medical education
